Spots Global Cancer Trial Database for Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer
Official Title: Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer
Study ID: NCT04635059
Conditions
Interventions
Study Description
Brief Summary: This is a single-arm, open-label study using pacritinib for patients with histologically confirmed prostate adenocarcinoma, status post definitive treatment and biochemical recurrence.
Detailed Description: This phase 2, single-arm, open-label study using pacritinib will treat patients with histologically confirmed prostate adenocarcinoma, status post definitive treatment and biochemical recurrence. The primary objective of this study is to determine the effect of pacritinib on the time to prostate-specific antigen (PSA) progression in patients with biochemical relapse of prostate cancer (defined as the length of time that a given subject will be alive and free from PSA progression per Prostate Cancer Working Group 3 (PCWG3) guidelines.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Contact Details
Name: Deepak Kilari, MD
Affiliation: Medical College of Wisconsin
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
